Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Magenta Therapeutics

Magenta Therapeutics
2015 FOUNDED
PUBLIC STATUS
61-70 EMPLOYEES
MGTA STOCK SYMBOL
$16.70 SHARE PRICE (As of Monday Closing)
Description

Magenta Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing and cell therapy. The pipeline of the company includes C100, C200, C300, MGTA-145, MGTA-156, E478 and G100.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 50 Hampshire Street
  • 8th Floor
  • Cambridge, MA 02139
  • United States

+1 (857) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Magenta Therapeutics’s full profile, request a free trial.

Magenta Therapeutics Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$5.31 - $21.00 $656M $16.56 -$4.14 216K 39.3M

Magenta Therapeutics Financials Summary

In Thousands,
USD
TTM
31-Mar-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 408,624 230,001
Revenue 0 0 0 0
EBITDA (63,856) (59,088) (35,351) (9,262)
Net Income (61,188) (57,515) (35,491) (9,431)
Total Assets 147,692 157,313 54,463 11,342
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Magenta Therapeutics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Magenta Therapeutics‘s full profile, request access.

Request full access to PitchBook

Magenta Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Magenta Therapeutics‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Magenta Therapeutics Competitors (14)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kiadis Pharma Formerly VC-backed Amsterdam, Netherlands 00 00000 000000000 00000
00 00000000 Venture Capital-Backed Glasgow, United Kingdom 00 000.00 0000000000 000.00
000000 00000000000 Failed Transaction (M&A) Cambridge, MA 000 00000 000000&0
00000000000 000000 Formerly VC-backed Abingdon, United Kingdom 000 00000 00000000000 00000
00000000 Formerly VC-backed Munich, Germany 000.00 000000&0 000.00
To view this company’s complete list of competitors, request access »

Magenta Therapeutics Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Magenta Therapeutics‘s full profile, request access.

Request full access to PitchBook

Magenta Therapeutics Executive Team (17)

Name Title Board
Seat
Contact
Info
Jason Gardner Ph.D Co-Founder, President, Chief Executive Officer & Board Member
Zoran Zdraveski JD Chief Legal Officer & Corporate Secretary
Michael Cooke Ph.D Chief Scientific Officer
Christina Isacson Ph.D Chief Business Officer
Alan Tyndall Ph.D Co-Founder and Scientific Advisor

1 Former Executive

You’re viewing 5 of 17 executives. Get the full list »

Magenta Therapeutics Board Members (11)

Name Representing Role Since Contact
Info
Alexis Borisy Third Rock Ventures Board Member 000 0000
Alison Lawton Self Board Member 000 0000
Blake Byers Ph.D GV Board Member 000 0000
Bruce Booth Ph.D Atlas Venture Board Member 000 0000
Chris Klee Self Board Observer 000 0000

2 Former Board Members

You’re viewing 5 of 11 board members. Get the full list »